81. 先天性副腎皮質酵素欠損症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AAV BBP-631
Adrenas Therapeutics Inc
2021 Phase 1/Phase 2 NCT04783181 Australia;United States;
ATR-101
Millendo Therapeutics US, Inc.
2018 Phase 2 EUCTR2017-004878-34-ES Brazil;France;Israel;Spain;
Millendo Therapeutics, Inc.
2018 Phase 2 EUCTR2017-004878-34-FR Brazil;France;Israel;Spain;
2016 Phase 2 NCT02804178 United States;
Abiraterone acetate
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011 Phase 1 NCT01495910 United States;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
2017 Phase 1 NCT02574910 United States;
Bone balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
CI-984, 17AA70, PD 132301-2
Millendo Therapeutics US, Inc.
2018 Phase 2 EUCTR2017-004878-34-ES Brazil;France;Israel;Spain;
Millendo Therapeutics, Inc.
2018 Phase 2 EUCTR2017-004878-34-FR Brazil;France;Israel;Spain;
Chronocort
Diurnal Limited
2021 Phase 3 NCT05063994 United States;
2011 Phase 1 NCT03051893 -
2010 Phase 1 NCT03019614 -
2007 Phase 1/Phase 2 NCT00519818 United States;
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Chronocort®
Diurnal Limited
2018 Phase 3 NCT03532022 United States;
2016 Phase 3 NCT02716818 United States;
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Federico II University
2016 Phase 4 NCT03760835 Italy;
Cortef
Diurnal Limited
2021 Phase 3 NCT05063994 United States;
2007 Phase 1/Phase 2 NCT00519818 United States;
Cortisol
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Cortison
Haukeland University Hospital
2012 - EUCTR2011-005822-23-NO Norway;
Cortisone acetate
Haukeland University Hospital
2013 Phase 2 NCT01771328 Norway;
Crinecerfont
Neurocrine Biosciences
2021 Phase 3 NCT04806451 Canada;France;Greece;Poland;United States;
2020 Phase 3 NCT04490915 Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-GR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-FR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-ES Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-DE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2019-004873-17-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GR Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GB Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2020-004381-19-PL Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
- Phase 3 EUCTR2020-004381-19-BE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-IT Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2020 Phase 3 EUCTR2019-004873-17-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
DIURF-006
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dectancyl
Hospices Civils de Lyon
2015 - EUCTR2015-003996-32-FR France;
Dexamethasone
Boston Children’s Hospital
2008 Phase 2 NCT00621985 United States;
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
Dexamethasone 0,1 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 0.5mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 1,5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 2mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dual release hydrocortisone (plenadren)
Federico II University
2016 Phase 4 NCT03760835 Italy;
Efmody 10 mg modified release hard capsules
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Efmody 5 mg modified release hard capsules
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Fludrocortisone
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
Flutamide
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
HYDROCORTISONE MICRONIZED
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
HYDROCORTISONE SODIUM SUCCINATE
Haukeland University Hospital
2014 Phase 2 EUCTR2011-005822-23-SE Norway;Sweden;
HYDROCORTISONE- hydrocortisone tablet
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Hormonal balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
Hydrocortisone
Boston Children’s Hospital
2008 Phase 2 NCT00621985 United States;
Diurnal Limited
2016 Phase 3 NCT03062280 United States;
2010 Phase 1 NCT03019614 -
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
Fujii Katsuya
2022 Phase 2 JPRN-jRCT2031210491 France;Japan;Turkey;US;
Haukeland University Hospital
2013 Phase 2 NCT01771328 Norway;
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
Hydrocortisone (Solucortef)
National Institutes of Health Clinical Center (CC)
2013 Phase 2 NCT01859312 United States;
Hydrocortisone 10mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 10mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 20mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone Modified Release Capsules
Diurnal Limited
2012 Phase 2 NCT01735617 United States;
Hydrocortisone sodium acetate
Baylor College of Medicine
2007 - NCT00529841 United States;
Hydrocortisone sodium phosphate
University Hospitals Bristol NHS Foundation Trust
2014 - EUCTR2012-001104-37-GB United Kingdom;
Hydrocortisone tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone withdrawal
Maria I. New
2007 - NCT00542841 Brazil;France;United States;
IDROCORTISONE
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Infacort
Diurnal Limited
2015 Phase 3 EUCTR2015-000458-40-DE Germany;
2015 Phase 3 EUCTR2014-002265-30-DE Germany;
Infacort®
Diurnal Limited
2016 Phase 3 NCT02733367 Germany;
Insulin pump (Medtronic)
National Institutes of Health Clinical Center (CC)
2013 Phase 2 NCT01859312 United States;
Letrozole
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
METFORMIN HYDROCHLORIDE
Ghent University Hospital
2014 Phase 3 EUCTR2013-002395-40-BE Belgium;
Metabolic balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
Metformine Sandoz 850 mg filmomhulde tabletten
Ghent University Hospital
2014 Phase 3 EUCTR2013-002395-40-BE Belgium;
NBI-74788
Neurocrine Biosciences
2019 Phase 2 NCT04045145 United States;
2018 Phase 2 NCT03525886 United States;
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-IT Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-GR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-FR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-ES Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-DE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2019-004873-17-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GR Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GB Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2020-004381-19-PL Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
- Phase 3 EUCTR2020-004381-19-BE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
NBI-77860
Neurocrine Biosciences
2015 Phase 1 NCT02349503 United States;
National Drug Code: 59762-0074
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Nevanimibe hydrochloride
Millendo Therapeutics US, Inc.
2018 Phase 2 NCT03669549 Brazil;Czechia;France;Israel;Spain;
Nifedipine
National Center for Research Resources (NCRR)
- Phase 1/Phase 2 NCT00000102 United States;
Pioglitazone
Radboud University
2005 - NCT00151710 Netherlands;
Prednisolone
Haukeland University Hospital
2014 Phase 2 EUCTR2011-005822-23-SE Norway;Sweden;
2012 - EUCTR2011-005822-23-NO Norway;
Prednisolone 1mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 2,5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisone
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
SPR001
Spruce Biosciences
2018 Phase 2 NCT03687242 United States;
2017 Phase 2 NCT03257462 United States;
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Spruce Biosciences, Inc.
2021 Phase 2 EUCTR2019-004765-40-PL Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004764-22-PL Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-SE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-NL Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-DK Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-DE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-SE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-NL Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-GB Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-DK Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-DE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Standard Care
Diurnal Limited
2018 Phase 3 NCT03532022 United States;
Standard glucocorticoid therapy
Diurnal Limited
2016 Phase 3 NCT02716818 United States;
University of Minnesota
2019 Phase 1 NCT03718234 United States;
Subcutaneous hydrocortisone
University of Minnesota
2019 Phase 1 NCT03718234 United States;
Tildacerfont
Spruce Biosciences
2021 Phase 2 NCT05128942 -
2020 Phase 2 NCT04544410 Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;
2020 Phase 2 NCT04457336 Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;
Adrenas Therapeutics Inc
2021 Phase 1/Phase 2 NCT04783181 Australia;United States;
ATR-101
Millendo Therapeutics US, Inc.
2018 Phase 2 EUCTR2017-004878-34-ES Brazil;France;Israel;Spain;
Millendo Therapeutics, Inc.
2018 Phase 2 EUCTR2017-004878-34-FR Brazil;France;Israel;Spain;
2016 Phase 2 NCT02804178 United States;
Abiraterone acetate
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011 Phase 1 NCT01495910 United States;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
2017 Phase 1 NCT02574910 United States;
Bone balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
CI-984, 17AA70, PD 132301-2
Millendo Therapeutics US, Inc.
2018 Phase 2 EUCTR2017-004878-34-ES Brazil;France;Israel;Spain;
Millendo Therapeutics, Inc.
2018 Phase 2 EUCTR2017-004878-34-FR Brazil;France;Israel;Spain;
Chronocort
Diurnal Limited
2021 Phase 3 NCT05063994 United States;
2011 Phase 1 NCT03051893 -
2010 Phase 1 NCT03019614 -
2007 Phase 1/Phase 2 NCT00519818 United States;
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Chronocort®
Diurnal Limited
2018 Phase 3 NCT03532022 United States;
2016 Phase 3 NCT02716818 United States;
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Federico II University
2016 Phase 4 NCT03760835 Italy;
Cortef
Diurnal Limited
2021 Phase 3 NCT05063994 United States;
2007 Phase 1/Phase 2 NCT00519818 United States;
Cortisol
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Cortison
Haukeland University Hospital
2012 - EUCTR2011-005822-23-NO Norway;
Cortisone acetate
Haukeland University Hospital
2013 Phase 2 NCT01771328 Norway;
Crinecerfont
Neurocrine Biosciences
2021 Phase 3 NCT04806451 Canada;France;Greece;Poland;United States;
2020 Phase 3 NCT04490915 Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-GR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-FR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-ES Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-DE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2019-004873-17-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GR Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GB Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2020-004381-19-PL Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
- Phase 3 EUCTR2020-004381-19-BE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-IT Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2020 Phase 3 EUCTR2019-004873-17-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
DIURF-006
Diurnal Ltd
2017 Phase 3 EUCTR2015-005448-32-SE Denmark;France;Germany;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005448-32-DE Denmark;France;Germany;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005448-32-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dectancyl
Hospices Civils de Lyon
2015 - EUCTR2015-003996-32-FR France;
Dexamethasone
Boston Children’s Hospital
2008 Phase 2 NCT00621985 United States;
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
Dexamethasone 0,1 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 0.5mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 1,5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Dexamethasone 2mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Dual release hydrocortisone (plenadren)
Federico II University
2016 Phase 4 NCT03760835 Italy;
Efmody 10 mg modified release hard capsules
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Efmody 5 mg modified release hard capsules
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
Fludrocortisone
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
Flutamide
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
HYDROCORTISONE MICRONIZED
Diurnal Limited
- Phase 3 EUCTR2021-004467-26-FR France;Japan;United States;
HYDROCORTISONE SODIUM SUCCINATE
Haukeland University Hospital
2014 Phase 2 EUCTR2011-005822-23-SE Norway;Sweden;
HYDROCORTISONE- hydrocortisone tablet
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Hormonal balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
Hydrocortisone
Boston Children’s Hospital
2008 Phase 2 NCT00621985 United States;
Diurnal Limited
2016 Phase 3 NCT03062280 United States;
2010 Phase 1 NCT03019614 -
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
Fujii Katsuya
2022 Phase 2 JPRN-jRCT2031210491 France;Japan;Turkey;US;
Haukeland University Hospital
2013 Phase 2 NCT01771328 Norway;
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
University of Texas Southwestern Medical Center
2023 Phase 2 NCT03548246 United States;
Hydrocortisone (Solucortef)
National Institutes of Health Clinical Center (CC)
2013 Phase 2 NCT01859312 United States;
Hydrocortisone 10mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 10mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone 20mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone Modified Release Capsules
Diurnal Limited
2012 Phase 2 NCT01735617 United States;
Hydrocortisone sodium acetate
Baylor College of Medicine
2007 - NCT00529841 United States;
Hydrocortisone sodium phosphate
University Hospitals Bristol NHS Foundation Trust
2014 - EUCTR2012-001104-37-GB United Kingdom;
Hydrocortisone tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Hydrocortisone withdrawal
Maria I. New
2007 - NCT00542841 Brazil;France;United States;
IDROCORTISONE
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Infacort
Diurnal Limited
2015 Phase 3 EUCTR2015-000458-40-DE Germany;
2015 Phase 3 EUCTR2014-002265-30-DE Germany;
Infacort®
Diurnal Limited
2016 Phase 3 NCT02733367 Germany;
Insulin pump (Medtronic)
National Institutes of Health Clinical Center (CC)
2013 Phase 2 NCT01859312 United States;
Letrozole
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1995 Phase 2 NCT00001521 United States;
METFORMIN HYDROCHLORIDE
Ghent University Hospital
2014 Phase 3 EUCTR2013-002395-40-BE Belgium;
Metabolic balance measurements
University Hospital, Caen
2012 Phase 2/Phase 3 NCT02552251 France;
Metformine Sandoz 850 mg filmomhulde tabletten
Ghent University Hospital
2014 Phase 3 EUCTR2013-002395-40-BE Belgium;
NBI-74788
Neurocrine Biosciences
2019 Phase 2 NCT04045145 United States;
2018 Phase 2 NCT03525886 United States;
Neurocrine Biosciences, Inc.
2021 Phase 3 EUCTR2020-004381-19-IT Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-GR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-FR Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-ES Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2020-004381-19-DE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
2021 Phase 3 EUCTR2019-004873-17-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004873-17-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GR Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-GB Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004873-17-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2020-004381-19-PL Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
- Phase 3 EUCTR2020-004381-19-BE Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States;
NBI-77860
Neurocrine Biosciences
2015 Phase 1 NCT02349503 United States;
National Drug Code: 59762-0074
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Nevanimibe hydrochloride
Millendo Therapeutics US, Inc.
2018 Phase 2 NCT03669549 Brazil;Czechia;France;Israel;Spain;
Nifedipine
National Center for Research Resources (NCRR)
- Phase 1/Phase 2 NCT00000102 United States;
Pioglitazone
Radboud University
2005 - NCT00151710 Netherlands;
Prednisolone
Haukeland University Hospital
2014 Phase 2 EUCTR2011-005822-23-SE Norway;Sweden;
2012 - EUCTR2011-005822-23-NO Norway;
Prednisolone 1mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-SE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
2015 Phase 3 EUCTR2015-000711-40-GB Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 2,5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DK Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5 mg Tablets
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-NL Denmark;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisolone 5mg Tablet
Diurnal Ltd
2016 Phase 3 EUCTR2015-000711-40-DE Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States;
Prednisone
Shanghai Jiao Tong University School of Medicine
2020 Phase 4 NCT04536662 China;
SPR001
Spruce Biosciences
2018 Phase 2 NCT03687242 United States;
2017 Phase 2 NCT03257462 United States;
Spruce Biosciences Inc.
2022 Phase 2 EUCTR2019-004764-22-IT Australia;Canada;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Spruce Biosciences, Inc.
2021 Phase 2 EUCTR2019-004765-40-PL Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004764-22-PL Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-SE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-NL Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-DK Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004765-40-DE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-SE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-NL Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-GB Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-DK Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004764-22-DE Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Standard Care
Diurnal Limited
2018 Phase 3 NCT03532022 United States;
Standard glucocorticoid therapy
Diurnal Limited
2016 Phase 3 NCT02716818 United States;
University of Minnesota
2019 Phase 1 NCT03718234 United States;
Subcutaneous hydrocortisone
University of Minnesota
2019 Phase 1 NCT03718234 United States;
Tildacerfont
Spruce Biosciences
2021 Phase 2 NCT05128942 -
2020 Phase 2 NCT04544410 Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;
2020 Phase 2 NCT04457336 Australia;Canada;Denmark;Germany;Netherlands;Spain;Sweden;United States;